Shire Closes Public Offering of Senior Notes

    Dublin, Ireland - September 23, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
    announced today that its wholly owned subsidiary, Shire Acquisitions
    Investments Ireland Designated Activity Company ("SAIIDAC"), issued $12.1
    billion aggregate principal amount of senior notes, consisting of four series
    of senior notes:

    $3.3 billion 1.900% Senior Notes due 2019;
    $3.3 billion 2.400% Senior Notes due 2021;
    $2.5 billion 2.875% Senior Notes due 2023; and
    $3.0 billion 3.200% Senior Notes due 2026

    Shire has used the net proceeds to fully repay amounts outstanding under its
    January 2016 bridge facilities agreement, which were used to finance its
    acquisition of Baxalta Incorporated ("Baxalta"). Shire intends to use the
    remaining net proceeds for general corporate purposes.

    The offering was made only by means of a base prospectus and related prospectus
    supplement. Copies of the base prospectus and final prospectus supplement may
    be obtained by contacting:

      * Barclays Capital Inc. by calling (toll-free from the U.S.) +1 888 603 5847;
      * Merrill Lynch, Pierce, Fenner & Smith Incorporated by calling (toll-free
        from the U.S.) +1 800 294 1322; or
      * Morgan Stanley & Co. LLC by calling (toll-free from the U.S.) +1 866 718
        1649.

    An effective registration statement is on file with the U.S. Securities and
    Exchange Commission ("SEC"), and a copy of the base prospectus and related
    prospectus supplement are also available on the SEC's website at www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of
    an offer to buy any securities nor shall there be any sale of these securities
    in any jurisdiction in which such an offer, solicitation or sale would be
    unlawful prior to registration or qualification under the securities laws of
    any such jurisdiction.

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Sarah Elton-Farr                seltonfarr@shire.com       +44 1256 894157   
                                                                                 
    Ian Karp                        ikarp@shire.com            +1 781 482 9018   
                                                                                 
    Robert Coates                   rcoates@shire.com          +44 1256 894874   
                                                                                 
    Media                                                                        
                                                                                 
    Gwen Fisher                     gfisher@shire.com          +1 484 595 9836   
                                                                                 
    Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083   

    NOTES TO EDITORS

    About Shire

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases and other highly specialized conditions. We strive to
    develop best-in-class products, many of which are available in more than 100
    countries, across core therapeutic areas including Hematology, Immunology,
    Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
    Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
    franchise in Oncology.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com

    Forward-Looking Statements

    Statements included herein that are not historical facts, including without
    limitation statements concerning future strategy, plans, objectives,
    expectations and intentions, the anticipated timing of clinical trials and
    approvals for, and the commercial potential of, inline or pipeline products are
    forward-looking statements. Such forward-looking statements involve a number of
    risks and uncertainties and are subject to change at any time. In the event
    such risks or uncertainties materialize, Shire's results could be materially
    adversely affected. The risks and uncertainties include, but are not limited
    to, the following:

      * Shire's products may not be a commercial success;
      * increased pricing pressures and limits on patient access as a result of
        governmental regulations and market developments may affect Shire's future
        revenues, financial condition and results of operations;
      * Shire conducts its own manufacturing operations for certain of its products
        and is reliant on third party contract manufacturers to manufacture other
        products and to provide goods and services.  Some of Shire's products or
        ingredients are only available from a single approved source for
        manufacture.  Any disruption to the supply chain for any of Shire's
        products may result in Shire being unable to continue marketing or
        developing a product or may result in Shire being unable to do so on a
        commercially viable basis for some period of time;
      * the manufacture of Shire's products is subject to extensive oversight by
        various regulatory agencies.  Regulatory approvals or interventions
        associated with changes to manufacturing sites, ingredients or
        manufacturing processes could lead to significant delays, an increase in
        operating costs, lost product sales, an interruption of research activities
        or the delay of new product launches;
      * certain of Shire's therapies involve lengthy and complex processes, which
        may prevent Shire from timely responding to market forces and effectively
        managing its production capacity;
      * Shire has a portfolio of products in various stages of research and
        development. The successful development of these products is highly
        uncertain and requires significant expenditures and time, and there is no
        guarantee that these products will receive regulatory approval;
      * the actions of certain customers could affect Shire's ability to sell or
        market products profitably. Fluctuations in buying or distribution patterns
        by such customers can adversely affect Shire's revenues, financial
        conditions or results of operations;
      * Shire's products and product candidates face substantial competition in the
        product markets in which it operates, including competition from generics;
      * adverse outcomes in legal matters, tax audits and other disputes, including
        Shire's ability to enforce and defend patents and other intellectual
        property rights required for its business, could have a material adverse
        effect on the combined company's revenues, financial condition or results
        of operations;
      * inability to successfully compete for highly qualified personnel from other
        companies and organizations;
      * failure to achieve the strategic objectives with respect to Shire's
        acquisition of NPS Pharmaceuticals, Inc., Dyax Corp. ("Dyax") or Baxalta
        may adversely affect Shire's financial condition and results of operations;
      * Shire's growth strategy depends in part upon its ability to expand its
        product portfolio through external collaborations, which, if unsuccessful,
        may adversely affect the development and sale of its products;
      * a slowdown of global economic growth, or economic instability of countries
        in which Shire does business, as well as changes in foreign currency
        exchange rates and interest rates, that adversely impact the availability
        and cost of credit and customer purchasing and payment patterns, including
        the collectability of customer accounts receivable;
      * failure of a marketed product to work effectively or if such a product is
        the cause of adverse side effects could result in damage to the Shire's
        reputation, the withdrawal of the product and legal action against Shire;
      * investigations or enforcement action by regulatory authorities or law
        enforcement agencies relating to Shire's activities in the highly regulated
        markets in which it operates may result in significant legal costs and the
        payment of substantial compensation or fines;
      * Shire is dependent on information technology and its systems and
        infrastructure face certain risks, including from service disruptions, the
        loss of sensitive or confidential information, cyber-attacks and other
        security breaches or data leakages that could have a material adverse
        effect on Shire's revenues, financial condition or results of operations;
      * Shire incurred substantial additional indebtedness to finance the Baxalta
        acquisition, which may decrease its business flexibility and increase
        borrowing costs;
      * difficulties in integrating Dyax or Baxalta into Shire may lead to the
        combined company not being able to realize the expected operating
        efficiencies, cost savings, revenue enhancements, synergies or other
        benefits at the time anticipated or at all; and
      * other risks and uncertainties detailed from time to time in Shire's filings
        with the SEC, including those risks outlined in "Risk Factors" and
        elsewhere in the prospectus supplement related to the offering, including
        the registration statement to which the offering relates and the prospectus
        contained therein and in "ITEM 1A: Risk Factors" in Shire's Quarterly
        Report on Form 10-Q for the quarter ended June 30, 2016.

    All forward-looking statements attributable to us or any person acting on our
    behalf are expressly qualified in their entirety by this cautionary statement.
    Readers are cautioned not to place undue reliance on these forward-looking
    statements that speak only as of the date hereof. Except to the extent
    otherwise required by applicable law, we do not undertake any obligation to
    update or revise forward-looking statements, whether as a result of new
    information, future events or otherwise.